Venous Thromboembolism in Advanced Disease
95,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
48 °P sammeln
  • Broschiertes Buch

This book provides an evidence-based, clinical guide to treating venous thromboembolism in palliative care, highlighting the uncertainties faced by clinicians when confronted with this common but complex issue, and dealing with both cancer and non-malignant diseases.

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book provides an evidence-based, clinical guide to treating venous thromboembolism in palliative care, highlighting the uncertainties faced by clinicians when confronted with this common but complex issue, and dealing with both cancer and non-malignant diseases.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr Simon Noble is a Clinical Senior Lecturer and Honorary Consultant in Palliative Medicine, Cardiff University and the Royal Gwent Hospital in Wales. His research interests include the management of venous thromboembolism in advanced cancer and the anticancer effects of low molecular weight heparins. He has chaired the APM Task group for the management of VTE in palliative care and is a Trustee of Lifeblood: a UK-based thrombosis charity. Dr Miriam Johnson is a Senior Lecturer in Palliative Medicine at Hull-York Medical School and Honorary Consultant to St. Catherine's Hospice, North Yorkshire, UK. Her research interests include the management of venous thromboembolism in advanced cancer, which formed the basis of her MD thesis. Her other research interests include the palliative care of patients with end stage heart failure, and the symptom management of breathlessness. She was part of the APM Task group for the management of VTE in palliative care. Dr Lee is the co-principal investigator of the CLOT study (Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer), a landmark study that established low-molecular-weight heparin as the treatment of choice for preventing recurrent venous thromboembolism in cancer patients. Her current research activities include studies in catheter-related thromobosis, diagnosis of deep vein thrombosis and pulmonary embolism in pregnant women, and thromboprophylaxis in patients undergoing major orthpaedic surgery. She is also involved in translational research exploring the role of coagulation in cancer biology. She is a co-chair of the subcommittee on Hemostasis and Malignancy of the International Society of Thrombosis and Haemostasis and has chaired various educational sessions at annual meetings at the American Society of Hematology and the American Society of Clinical Oncology.